NEW YORK (GenomeWeb) – Premaitha Health has reported that its cell-free DNA-based screen for fetal aneuploidies performed with perfect sensitivity and specificity.

Trisomies 13, 18, and 21 have been increasing in incidence, according to the US Centers for Disease Control and Prevention. But, common screening approaches based on ultrasound findings and other markers have false-positive rates that lead many women to seek an invasive diagnostic procedure like an amniocentesis or chorionic villus sampling when it may not be necessary.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.